JP2010521516A5 - - Google Patents

Download PDF

Info

Publication number
JP2010521516A5
JP2010521516A5 JP2009554019A JP2009554019A JP2010521516A5 JP 2010521516 A5 JP2010521516 A5 JP 2010521516A5 JP 2009554019 A JP2009554019 A JP 2009554019A JP 2009554019 A JP2009554019 A JP 2009554019A JP 2010521516 A5 JP2010521516 A5 JP 2010521516A5
Authority
JP
Japan
Prior art keywords
pain
compound
treatment
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2009554019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010521516A (ja
Filing date
Publication date
Priority claimed from GB0705424A external-priority patent/GB0705424D0/en
Priority claimed from GB0712390A external-priority patent/GB0712390D0/en
Application filed filed Critical
Priority claimed from PCT/EP2008/053285 external-priority patent/WO2008113818A1/en
Publication of JP2010521516A publication Critical patent/JP2010521516A/ja
Publication of JP2010521516A5 publication Critical patent/JP2010521516A5/ja
Ceased legal-status Critical Current

Links

JP2009554019A 2007-03-21 2008-03-19 疼痛および過敏性腸症候群の治療におけるキノリン誘導体の使用 Ceased JP2010521516A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0705424A GB0705424D0 (en) 2007-03-21 2007-03-21 Use of compounds in the treatment of pain and irritable bowel syndrome
GB0712390A GB0712390D0 (en) 2007-06-26 2007-06-26 Use of compounds in the treatment of pain and irritable bowel syndrome
PCT/EP2008/053285 WO2008113818A1 (en) 2007-03-21 2008-03-19 Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome

Publications (2)

Publication Number Publication Date
JP2010521516A JP2010521516A (ja) 2010-06-24
JP2010521516A5 true JP2010521516A5 (enExample) 2011-04-28

Family

ID=39564633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009554019A Ceased JP2010521516A (ja) 2007-03-21 2008-03-19 疼痛および過敏性腸症候群の治療におけるキノリン誘導体の使用

Country Status (5)

Country Link
US (1) US20100041672A1 (enExample)
EP (1) EP2120950B1 (enExample)
JP (1) JP2010521516A (enExample)
ES (1) ES2389958T3 (enExample)
WO (1) WO2008113818A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754238B2 (en) 2003-07-22 2014-06-17 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
ES2373617T3 (es) 2007-03-23 2012-02-07 Abbott Gmbh & Co. Kg Compuestos de quinolina adecuados para tratar trastornos que responden a la modulación del receptor 5-ht6 de serotonina.
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
EP2763676B1 (en) 2011-10-03 2019-12-25 The University of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
WO2013134725A1 (en) * 2012-03-08 2013-09-12 Spr Therapeutics, Llc System and method for treatment of pain related to limb joint replacement surgery
US20160038484A1 (en) * 2013-04-03 2016-02-11 The University Of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
TW201720439A (zh) 2015-07-15 2017-06-16 Axovant Sciences Gmbh 用於預防及治療與神經退化性疾病相關的幻覺之作為5-ht2a血清素受體的二芳基及芳基雜芳基脲衍生物
CN109069450A (zh) * 2016-02-05 2018-12-21 法奈克斯公司 神经障碍的新的组合疗法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5596001A (en) * 1993-10-25 1997-01-21 Pfizer Inc. 4-aryl-3-(heteroarylureido)quinoline derivatves
US5576338A (en) * 1995-02-15 1996-11-19 Merck Frosst Canada, Inc. Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
US20010051719A1 (en) * 1996-12-19 2001-12-13 Smithkline Beecham P.L.C. Novel compounds
US6207679B1 (en) * 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
US6376670B1 (en) * 1997-06-19 2002-04-23 Sepracor Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
CA2293418A1 (en) * 1997-06-19 1998-12-23 Michael Z. Hoemann Quinoline-indole antimicrobial agents, uses and compositions related thereto
JP2002511097A (ja) * 1997-07-11 2002-04-09 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 5−ht▲下6▼レセプターアンタゴニストであるスルホンアミド誘導体およびその製造方法
GB9801392D0 (en) * 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
US6403808B1 (en) * 1999-12-10 2002-06-11 Virginia Commonwealth University Selective 5-HT6 receptor ligands
US6310212B1 (en) * 2000-03-28 2001-10-30 Neurogen Corporation 4-substituted quinoline derivatives
GB0021450D0 (en) * 2000-08-31 2000-10-18 Smithkline Beecham Plc Novel compounds
KR100823908B1 (ko) * 2000-10-20 2008-04-21 바이오비트럼 에이비(피유비엘) 2-, 3-, 4-, 또는 5-치환-n1-(벤젠술포닐)인돌 및 이의치료 용도
DE10053813A1 (de) * 2000-10-30 2002-05-08 Bayer Ag Neue Verwendung von Sulfonamiden
AU2002215047A1 (en) * 2000-11-21 2002-06-03 Smithkline Beecham Plc Isoquinoline derivatives useful in the treatment of cns disorders
WO2002041889A2 (en) * 2000-11-24 2002-05-30 Smithkline Beecham P.L.C. Indolsulfonyl compounds useful in the treatment of cns disorders
JP4187642B2 (ja) * 2001-06-07 2008-11-26 エフ.ホフマン−ラ ロシュ アーゲー 5−ht6受容体親和性を有する新規インドール誘導体
ITRM20010356A1 (it) * 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
WO2003062205A1 (en) * 2001-12-21 2003-07-31 Smithkline Beecham P.L.C. 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders
EP1472544A2 (en) * 2002-02-01 2004-11-03 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
US20050090485A1 (en) * 2002-02-13 2005-04-28 Bromidge Steven M. 7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders
ES2386828T3 (es) * 2002-03-27 2012-08-31 Glaxo Group Limited Derivados de quinolina y su uso como ligandos 5-HT6
US7943639B2 (en) * 2002-06-20 2011-05-17 Proximagen Limited Compounds
ES2291722T3 (es) * 2002-12-03 2008-03-01 Hoffmann La Roche Aminoalcoxiindoles como ligandos 5-ht6-receptores para el tratamiento de transtornos del snc.
AU2004213375A1 (en) * 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-Hydroxytryptamine-6 ligands
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
GB0321473D0 (en) * 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0322510D0 (en) * 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
PT1667975E (pt) * 2003-09-26 2008-02-29 Glaxo Group Ltd Forma polimórfica de 3-fenilsulfonil-8-piperazin-1-il-quinolina
SE0302760D0 (sv) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
WO2005066157A1 (en) * 2004-01-02 2005-07-21 Suven Life Sciences 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators
GB0407025D0 (en) * 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
BRPI0511874A (pt) * 2004-06-09 2008-01-15 Glaxo Group Ltd derivados da pirrolopiridina
GB0425548D0 (en) * 2004-11-19 2004-12-22 Glaxo Group Ltd Radiolabelled ligands

Similar Documents

Publication Publication Date Title
JP2010521516A5 (enExample)
JP2013518107A5 (enExample)
JP2011518833A5 (enExample)
JP2012255026A5 (enExample)
JP2016522835A5 (enExample)
JP2013523733A5 (enExample)
JP2011528658A5 (enExample)
JP2015512931A5 (enExample)
JP2017537066A5 (enExample)
JP2013537203A5 (enExample)
JP2013500986A5 (enExample)
JP2009545527A5 (enExample)
JP2014500861A5 (enExample)
JP2017528503A5 (enExample)
JP2017531038A5 (enExample)
JP2017520613A5 (enExample)
JP2012507535A5 (enExample)
JP2014521744A5 (enExample)
JP2011513410A5 (enExample)
JP2007302689A5 (enExample)
JP2015508092A5 (enExample)
JP2015521156A5 (enExample)
JP2016522254A5 (enExample)
JP2017511377A5 (enExample)
JP2015516419A5 (enExample)